In utero per - and polyfluoroalkyl substances (PFAS) exposure and changes in infant T helper cell development among

Darline Castro Meléndez1, Nathan Laniewski2, Todd A Jusko3

  • 1Department of Immunology, Microbiology and Virology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States.

Insights

Prenatal exposure to PFAS chemicals alters infant T-cell development, impacting immune responses. Higher PFAS levels were linked to changes in T-follicular helper and T-helper 2 cells by 12 months of age.

Area of Science:

  • Immunology
  • Environmental Health
  • Developmental Biology

Background:

  • Prenatal exposure to toxicants like PFAS can disrupt immune development.
  • T-cells are crucial for orchestrating immune responses.
  • Early life PFAS exposure effects on infant T-cell development are not well understood.

Purpose of the Study:

  • To model longitudinal changes in CD4+ T-cell subpopulations from birth to 12 months.
  • To investigate the association between in-utero PFAS exposure and infant T-cell development.

Main Methods:

  • Maternal-infant dyads were recruited (n=200) and followed for one year.
  • Maternal serum PFAS concentrations were measured during pregnancy.
  • Infant lymphocyte frequencies were assessed using mass cytometry and analyzed with linear mixed-effects models.

Main Results:

  • In-utero PFAS exposure correlated with changes in multiple infant CD4+ T-cell subpopulations.
  • Significant associations were observed for T-follicular helper (Tfh) and T-helper 2 (Th2) cells at 12 months.
  • Increased PFOS exposure was linked to lower Tfh and higher Th2 cell percentages.

Conclusions:

  • Maternal PFAS exposure is associated with cell-specific alterations in the infant T-cell compartment.
  • These changes may impact the development of well-regulated, protective immunity in children.
  • Further research is needed to explore PFAS-associated T-cell distribution and adverse immune outcomes.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.1K
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.4K